Want to see CLDI full AI Analyst Report?
Calidi Biotherapeutics (CLDI) AI Stock Analysis
Calidi Biotherapeutics
(NYSE MKT:CLDI)
The stock scores at the minimum due to severe fundamental and technical weakness. The company is pre-revenue with high cash burn and faces an NYSE compliance issue, while the stock price is in a deep downtrend with oversold, bearish momentum. Recent financing and pipeline progress are overshadowed by immediate financial and listing risks.
Calidi Biotherapeutics (CLDI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.78M
- Dividend Yield
- ―
- Average Volume (3M)
- 130.90K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 1.24
- Revenue Growth
- ―
- EPS Growth
- 53.95%
- Country
- US
- Employees
- 29
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Calidi Biotherapeutics Business Overview & Revenue Model
Company Description
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (dono...
How the Company Makes Money
Calidi Biotherapeutics is a clinical-stage biopharmaceutical company and, as such, it generally does not generate meaningful recurring revenue from product sales until a therapy is approved and commercialized. Specific, company-reported revenue break...
Calidi Biotherapeutics Financial Statement Overview
Summary
Pre-revenue with persistent net losses and high cash burn, though losses are narrowing and the balance sheet shows modest improvement with positive equity and low debt. Overall financial health remains very weak for a clinical-stage biotech.
Income Statement
15Very NegativeBalance Sheet
30NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 45.00K | 449.00K |
| Gross Profit | -426.00K | -1.65M | 0 | -1.26M | -229.00K | 355.00K |
| EBITDA | -15.62M | -18.19M | -19.73M | -24.20M | -25.00M | -9.45M |
| Net Income | -17.47M | -19.91M | -22.14M | -29.22M | -25.43M | -10.93M |
Balance Sheet | ||||||
| Total Assets | 7.20M | 8.86M | 14.18M | 10.02M | 2.60M | 3.39M |
| Cash, Cash Equivalents and Short-Term Investments | 4.07M | 5.60M | 9.59M | 2.05M | 372.00K | 2.14M |
| Total Debt | 1.94M | 2.56M | 7.04M | 7.24M | 5.99M | 5.18M |
| Total Liabilities | 4.07M | 5.10M | 12.21M | 18.25M | 53.04M | 26.00M |
| Stockholders Equity | 3.13M | 3.76M | 1.53M | -8.23M | -50.44M | -22.61M |
Cash Flow | ||||||
| Free Cash Flow | -17.81M | -21.41M | -19.71M | -27.57M | -13.64M | -7.98M |
| Operating Cash Flow | -17.75M | -21.29M | -19.69M | -26.98M | -13.21M | -7.77M |
| Investing Cash Flow | -144.00K | -170.00K | -16.00K | -478.00K | -494.00K | -215.00K |
| Financing Cash Flow | 16.81M | 17.46M | 27.36M | 29.04M | 12.09M | 9.81M |
Calidi Biotherapeutics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDI, the sentiment is Negative. The current price of 0.67 is below the 20-day moving average (MA) of 0.81, below the 50-day MA of 1.06, and below the 200-day MA of 4.35, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 26.38 is Positive, neither overbought nor oversold. The STOCH value of 29.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLDI.
Calidi Biotherapeutics Risk Analysis
Calidi Biotherapeutics disclosed 85 risk factors in its most recent earnings report. Calidi Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksCalidi Biotherapeutics Peers Comparison
Overall Rating
JAGX42Neutral
ADIL40Underperform- CLDI37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JAGX | 42Neutral | $3.76M | 0.00 | 762.51% | ― | 135.52% | 85.50% |
| ADIL | 40Underperform | $10.00M | -0.30 | -1693.21% | ― | ― | 45.78% |
| CLDI | 37Underperform | $2.53M | -0.01 | -372.86% | ― | ― | 53.95% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CLDI | Calidi Biotherapeutics, Inc. | 0.66 | -23.34 | -97.26% | |
| JAGX | Jaguar Animal Health Inc. | 0.88 | -637.08 | -99.86% | |
| ADIL | Adial Pharma | 3.81 | -4.32 | -53.15% | |
| CDIO | Cardio Diagnostics Holdings Inc. | 1.67 | -1.95 | -53.87% |
Calidi Biotherapeutics Corporate Events
Calidi Biotherapeutics Addresses NYSE American Compliance Notice
NegativeOn September 21, 2026, Calidi Biotherapeutics received a notification from NYSE American that it was no longer in compliance with the exchange’s continued listing standard requiring at least $4.0 million in stockholders’ equity for compan...
Calidi Biotherapeutics Announces Registered Direct Stock Offering
PositiveOn September 17, 2026, Calidi Biotherapeutics, Inc. entered into a stock purchase agreement with accredited investors and qualified institutional buyers for a registered direct offering of 1,025,640 shares of common stock at $1.17 per share. The offe...
Calidi Biotherapeutics Reports Quarterly Results and Pipeline Progress
PositiveOn August 13, 2026, Calidi Biotherapeutics reported financial results for the quarter ended June 30, 2026, alongside operational updates that underscore progress in its RedTail virotherapy platform. The company received positive pre-IND feedback from...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 20, 2026